The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Open accessAbstract
Purpose: To assess efficacy and safety of single-agent bortezomib in previously untreated patients with multiple myeloma, investigate prevalence of baseline and treatment-emergent polyneuropathy, and identify molecular markers associated with response and neuropathy. Patients and Methods: Patients received bortezomib 1.3 mg/m 2 on days 1, 4, 8, and 11, for up to eight 21-day cycles. A subset of patients underwent neurophysiologic evaluation pre- and post-treatment. Bone marrow aspirates were performed at baseline for exploratory whole-genome analyses. Results: Among 64 patients, 41% had partial response or better, including 9% complete/near-complete responses; median duration of response was 8.4 months. Response rates did not differ in the presence or absence of adverse cytogenetics. After median follow-up of 29 months, median time to progression was 17.3 months. Median overall survival had not been reached; estimated 1-year survival was 92%. Thirty-two patients successfully underwent optional stem-cell transplantation. Bortezomib treatment was generally well tolerated. At baseline, 20% of patients had sensory polyneuropathy. Sensory polyneuropathy developed during treatment in 64% of patients (grade 3 in 3%), but proved manageable and resolved in 85% within a median of 98 days. Neurologic examination, neurophysiologic testing, and measurements of epidermal nerve fiber densities in 35 patients confirmed pretreatment sensory neuropathy in 20% and new or worsening neuropathy in 63%. Pharmacogenomic analyses identified molecular markers of response and treatment-emergent neuropathy, which will require future study. Conclusion: Single-agent bortezomib is effective in previously untreated myeloma. Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 4×
“Response was assessed after every two cycles according to European Group for Blood and Marrow Transplantation criteria,(20) modified to include near CR (nCR; CR, but immunofixation-positive for M-protein).(7) Patients were also evaluated for very good partial response (VGPR; 90% M-protein reduction) per International…”
BackgroundMethodResultInfluentialSelf-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
England, J. D., Gronseth, G. S., Franklin, G., Miller, R. G., Asbury, A. K., Carter, G. T., Cohen, J. A., Fisher, M. A., Howard, J. F., Kinsella, L. J., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149522.32823.ea · Cited by 742
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Self-citationRichardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Self-citationThalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2007) · Blood · doi:10.1182/blood-2006-08-036947 · Cited by 513
Self-citationMulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
Self-citationCalhoun, E. A., Welshman, E. E., Chang, C.-H., Lurain, J. R., Fishman, D. A., Hunt, T. L., & Cella, D. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13603.x · Cited by 392
Mateos, M.-V., Hernández, J.-M., Hernández, M.-T., Gutiérrez, N.-C., Palomera, L., Fuertes, M., Díaz-Mediavilla, J., Lahuerta, J.-J., de la Rubia, J., Terol, M.-J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-019778 · Cited by 389
Self-citationPainful sensory neuropathy: Prospective evaluation using skin biopsy
Periquet, M. I., Novak, V., Collins, M. P., Nagaraja, H. N., Erdem, S., Nash, S. M., Freimer, M. L., Sahenk, Z., Kissel, J. T., & Mendell, J. R. (1999) · Neurology · doi:10.1212/wnl.53.8.1641 · Cited by 377
Harousseau, J., Attal, M., Leleu, X. P., Troncy, J., Pegourié, B., Stoppa, A., Hulin, C., Benboubker, L., Fuzibet, J., Renaud, M., et al. (2006) · PubMed · Cited by 367
Primary dexamethasone treatment of multiple myeloma
Alexanian, R., Dimopoulos, M., Delasalle, K., & Barlogie, B. (1992) · Blood · doi:10.1182/blood.v80.4.887.887 · Cited by 366
Rajkumar, S. V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Signatures of the Immune Response
Shaffer, A. L., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Lam, L. T., Pickeral, O. K., & Staudt, L. M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00194-7 · Cited by 314
Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Self-citationEpidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies
Herrmann, D. N., Griffin, J. W., Hauer, P., Cornblath, D. R., & McArthur, J. C. (1999) · Neurology · doi:10.1212/wnl.53.8.1634 · Cited by 272
Jagannath, S., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Cowan, J. M., & Anderson, K. C. (2007) · Leukemia · doi:10.1038/sj.leu.2404442 · Cited by 264
Self-citationLenalidomide and Venous Thrombosis in Multiple Myeloma
(2006) · New England Journal of Medicine · doi:10.1056/nejmc053530 · Cited by 232
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0061 · Cited by 226
Self-citationThe spectrum of peripheral neuropathy in myeloma
Kelly, J. J., Kyle, R. A., Miles, J. M., et al. (1981) · Neurology · doi:10.1212/wnl.31.1.24 · Cited by 216
Mileshkin, L., Stark, R., Day, B., Seymour, J. F., Zeldis, J. B., & Prince, H. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6689 · Cited by 211
Distal symmetrical polyneuropathy: Definition for clinical research
England, J. D., Gronseth, G. S., Franklin, G., Miller, R. G., Asbury, A. K., Carter, G. T., Cohen, J. A., Fisher, M. A., Howard, J. F., Kinsella, L. J., et al. (2005) · Muscle & Nerve · doi:10.1002/mus.20233 · Cited by 203
Facon, T. (2006) · Blood · doi:10.1182/blood-2005-04-1588 · Cited by 178
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 172
Self-citationNeurological aspects of multiple myeloma and related disorders
Dispenzieri, A., & Kyle, R. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.024 · Cited by 161
Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
Bennett, C. L., Angelotta, C., Yarnold, P. R., Evens, A. M., Zonder, J. A., Raisch, D. W., & Richardson, P. G. G. (2006) · JAMA · doi:10.1001/jama.296.21.2558-c · Cited by 149
Self-citationNeurologic Complications of Myelomatosis
SILVERSTEIN, A., & DONIGER, D. E. (1963) · Archives of Neurology · doi:10.1001/archneur.1963.00460110102011 · Cited by 136
Popat, R., Oakervee, H. E., Hallam, S. L., Curry, N. S., Odeh, L., Foot, N. J., Esseltine, D.-L. W., Drake, M. B., Morris, C., & Cavenagh, J. D. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.06997.x · Cited by 135
Self-citationRichardson, P. G. G., Schlossman, R. L., Jagannath, S., Alsina, M., Desikan, R. K., Blood, E., Weller, E. A., Mitsiades, C. S., Hideshima, T., Davies, F. E., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.875 · Cited by 130
Self-citationNeuropathy in multiple myeloma treated with thalidomide
Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267271.18475.fe · Cited by 126
Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N., Ackermann, J., Küenburg, E., Wieser, R., Zielinski, C. C., & Drach, J. W. (2006) · Leukemia · doi:10.1038/sj.leu.2404459 · Cited by 121
Rosiñol, L., Oriol, A., Mateos, M., Sureda, A. M., García-Sánchez, P., Gutierrez, N. C., Alegre, A. M., Lahuerta, J. J., de la Rubia, J., Herrero, C. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3323 · Cited by 118
Harousseau, J., Mathiot, C., Attal, M., Marit, G., Caillot, D., Hulin, C., Facon, T. T. F., Webb, I. J., Avet‐Loiseau, H., & Moreau, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8505 · Cited by 77
Cavo, M., Patriarca, F. F., Tacchetti, P., Galli, M., Perrone, G., Petrucci, M. T., Brioli, A., Bringhen, S., Pantani, L., Tosi, P., et al. (2007) · Blood · doi:10.1182/blood.v110.11.73.73 · Cited by 77
The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma
Richardson, P. G. G., Hideshima, T., Mitsiades, C. S., & Anderson, K. C. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0015 · Cited by 74
Self-citationRichardson, P. G. G., Jagannath, S., Avigan, D., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D. S., McKenney, M., et al. (2006) · Blood · doi:10.1182/blood.v108.11.405.405 · Cited by 68
Self-citationHulin, C., Facon, T. T. F., Rodon, P., Pegourié, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Voillat, L., Mathiot, C., et al. (2007) · Blood · doi:10.1182/blood.v110.11.75.75 · Cited by 67
Bortezomib in combination with dexamethasone for relapsed multiple myeloma
Kropff, M. H., Bisping, G., Wenning, D., Volpert, S., Tchinda, J., Berdel, W. E., & Kienast, J. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.11.004 · Cited by 63
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Rajkumar, S. V., Fonseca, R., Geyer, S. M., Allmer, C., Witzig, T. E., Lust, J. A., Greipp, P. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704633 · Cited by 59
Tariman, J. D., Love, G., McCullagh, E. J., & Sandifer, S. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.s1.29-35 · Cited by 52
Oakervee, H. E., Popat, R., & Cavenagh, J. D. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701540991 · Cited by 31
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Manochakian, R., Miller, K. C., & Chanan-Khan, A. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-978 · Cited by 29
Self-citationCutaneous sensory nerve fibers are decreased in number after peripheral and central nerve damage
Wallengren, J., Tegner, E., & Sundler, F. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.118540 · Cited by 18
Expanding Role of Bortezomib in Multiple Myeloma
Colson, K., Doss, D. S., Swift, R. A., et al. (2008) · Cancer Nursing · doi:10.1097/01.ncc.0000305733.80592.8e · Cited by 9
Self-citation
Cited by
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citationChemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Self-citationChemotherapy-induced neuropathy: A comprehensive survey
Miltenburg, N. C., & Boogerd, W. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.04.004 · Cited by 431
Metadata
- Authors
- Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., Kesari, S., Briemberg, H. R., Schlossman, R. L., Munshi, N. C., Heffner, L. T., Doss, D., Esseltine, D.-L., Weller, E., Anderson, K. C., & Amato, A. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-20
- Volume
- 27
- Issue
- 21
- Pages
- 3518-3525
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2172122039
- Cited by
- 274
- References
- 52
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.